484 related articles for article (PubMed ID: 3888488)
1. Clinical pharmacokinetics of the third generation cephalosporins.
Balant L; Dayer P; Auckenthaler R
Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488
[TBL] [Abstract][Full Text] [Related]
2. Third-generation cephalosporins: a critical evaluation.
Barriere SL; Flaherty JF
Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of cephalosporins.
Christ W
Infection; 1991; 19 Suppl 5():S244-52. PubMed ID: 1783440
[TBL] [Abstract][Full Text] [Related]
4. Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.
Garzone P; Lyon J; Yu VL
Drug Intell Clin Pharm; 1983; 17(7-8):507-15. PubMed ID: 6347596
[TBL] [Abstract][Full Text] [Related]
5. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards DM; Heel RC
Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefoperazone: a review.
Craig WA; Gerber AU
Drugs; 1981; 22 Suppl 1():35-45. PubMed ID: 6456890
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and metabolism of the cephalosporins].
Graninger W
Wien Klin Wochenschr Suppl; 1983; 142():11-5. PubMed ID: 6580781
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.
Greenfield RA; Gerber AU; Craig WA
Rev Infect Dis; 1983; 5 Suppl 1():S127-36. PubMed ID: 6221382
[TBL] [Abstract][Full Text] [Related]
9. New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
Jones RN; Erwin ME; Bale M
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):73-80. PubMed ID: 1580897
[TBL] [Abstract][Full Text] [Related]
10. Third-generation cephalosporins.
Klein NC; Cunha BA
Med Clin North Am; 1995 Jul; 79(4):705-19. PubMed ID: 7791418
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of newer cephalosporins. An update.
Thompson JW; Jacobs RF
Drug Saf; 1993 Aug; 9(2):132-42. PubMed ID: 8397890
[TBL] [Abstract][Full Text] [Related]
12. Cefetamet pivoxil clinical pharmacokinetics.
Blouin RA; Stoeckel K
Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
[TBL] [Abstract][Full Text] [Related]
13. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
Adu A; Armour CL
Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766
[TBL] [Abstract][Full Text] [Related]
14. Third generation cephalosporins.
Donowitz GR
Infect Dis Clin North Am; 1989 Sep; 3(3):595-612. PubMed ID: 2671141
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?
Noble JT; Barza M
Drugs; 1985 Sep; 30(3):175-81. PubMed ID: 3899596
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic properties of the cephalosporins.
Bergan T
Drugs; 1987; 34 Suppl 2():89-104. PubMed ID: 3319507
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the third-generation cephalosporins.
Harding SM
Am J Med; 1985 Aug; 79(2A):21-4. PubMed ID: 4025382
[TBL] [Abstract][Full Text] [Related]
18. [Third generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) in the prevention and treatment of experimental plague in albino mice].
Ryzhko IV; Tsuraeva RI; Pasiukov VV; Samokhodkina ED; Shcherbaniuk AI
Antibiot Khimioter; 1996 May; 41(5):35-8. PubMed ID: 9054316
[TBL] [Abstract][Full Text] [Related]
19. A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.
Neu HC
Ther Drug Monit; 1981; 3(2):121-8. PubMed ID: 6455787
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
